Jazz, AbCellera sign deal for T-cell engagers in solid tumours

Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of TCE multispecific antibodies for GI cancers and other solid tumours. AbCellera will conduct discovery and early-stage research activities on two initial programmes. The collaboration grants Jazz Pharmaceuticals exclusive worldwide rights to develop and commercialise antibodies from the partnership. Credit: Tada Images / Shutterstock.com. Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of T-cell-engaging multispecific antibodies, or T-cell engagers (TCEs), for gastrointestinal (GI) cancers and other solid tumours. The collaboration involves up…

Source: Pharmaceutical Technology